iNtRON Biotechnology Inc - Asset Resilience Ratio
iNtRON Biotechnology Inc (048530) has an Asset Resilience Ratio of 10.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 048530 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how iNtRON Biotechnology Inc's Asset Resilience Ratio has changed over time. See 048530 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down iNtRON Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see iNtRON Biotechnology Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩8.58 Billion | 10.9% |
| Total Liquid Assets | ₩8.58 Billion | 10.90% |
Asset Resilience Insights
- Moderate Liquidity: iNtRON Biotechnology Inc has 10.90% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
iNtRON Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare iNtRON Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for iNtRON Biotechnology Inc (2012–2024)
The table below shows the annual Asset Resilience Ratio data for iNtRON Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.85% | ₩15.42 Billion ≈ $10.45 Million |
₩86.37 Billion ≈ $58.53 Million |
-40.14pp |
| 2023-12-31 | 57.99% | ₩57.18 Billion ≈ $38.75 Million |
₩98.61 Billion ≈ $66.83 Million |
+24.40pp |
| 2022-12-31 | 33.59% | ₩47.35 Billion ≈ $32.09 Million |
₩140.96 Billion ≈ $95.53 Million |
-20.85pp |
| 2021-12-31 | 54.44% | ₩83.49 Billion ≈ $56.58 Million |
₩153.37 Billion ≈ $103.93 Million |
-11.37pp |
| 2020-12-31 | 65.81% | ₩66.16 Billion ≈ $44.84 Million |
₩100.54 Billion ≈ $68.13 Million |
+2.50pp |
| 2019-12-31 | 63.32% | ₩56.37 Billion ≈ $38.20 Million |
₩89.03 Billion ≈ $60.34 Million |
+24.70pp |
| 2018-12-31 | 38.62% | ₩21.16 Billion ≈ $14.34 Million |
₩54.80 Billion ≈ $37.13 Million |
-3.16pp |
| 2017-12-31 | 41.77% | ₩19.06 Billion ≈ $12.92 Million |
₩45.63 Billion ≈ $30.92 Million |
+2.51pp |
| 2016-12-31 | 39.26% | ₩23.40 Billion ≈ $15.86 Million |
₩59.61 Billion ≈ $40.39 Million |
+29.03pp |
| 2015-12-31 | 10.23% | ₩4.13 Billion ≈ $2.80 Million |
₩40.37 Billion ≈ $27.36 Million |
-3.92pp |
| 2012-12-31 | 14.15% | ₩2.78 Billion ≈ $1.88 Million |
₩19.64 Billion ≈ $13.31 Million |
-- |
About iNtRON Biotechnology Inc
iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.